Cancer, advanced or metastatic solid tumor/s
JANXJanux TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Failed discontinued for JANX008 (EGFR-TRACTr) in Cancer, advanced or metastatic solid tumor/s. The expected timing is based on the latest available company guidance and may change.
2/26/24- Interim data reported. Continuing in the DE and optimization portion. 2/27/25- Ongoing enrollment. 11/6/25- Additional data in Q4 2025. 12/23/25:- Phase 1a dose escalation completed; expansion cohorts initiated for selected EGFR-positive solid tumors. 02/26/26:- Phase 1 trial and expansion cohorts ongoing; additional JANX008 clinical update expected in 2026. 04/27/26:- Discontinued JANX008 after internal review; responses seen but insufficient overall.
Verification
Confirm timing and program details against the company announcement or filing.